{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:08:48Z","timestamp":1789520928528,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000009","name":"National Institute of Health","doi-asserted-by":"publisher","award":["R01CA174305"],"award-info":[{"award-number":["R01CA174305"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"National Institute of Health","doi-asserted-by":"publisher","award":["R01CA219399"],"award-info":[{"award-number":["R01CA219399"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"National Institute of Health","doi-asserted-by":"publisher","award":["R01CA223788"],"award-info":[{"award-number":["R01CA223788"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"National Institute of Health","doi-asserted-by":"publisher","award":["R50 CA211241"],"award-info":[{"award-number":["R50 CA211241"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.actbio.2020.01.039","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T16:23:47Z","timestamp":1580228627000},"page":"289-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy"],"prefix":"10.1016","volume":"106","author":[{"given":"Jingjing","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoya","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3585-4391","authenticated-orcid":false,"given":"Yichao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieni","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangyi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Parise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binfeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.actbio.2020.01.039_bib0001","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.actbio.2020.01.039_bib0002","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris 3rd","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.actbio.2020.01.039_bib0003","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0090-9556(25)08805-1","article-title":"Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs","volume":"20","author":"Shipley","year":"1992","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.actbio.2020.01.039_bib0004","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","article-title":"nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer","volume":"2","author":"Frese","year":"2012","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.actbio.2020.01.039_bib0005","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1093\/carcin\/bgt227","article-title":"Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer","volume":"34","author":"Awasthi","year":"2013","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.actbio.2020.01.039_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.actbio.2020.01.039_bib0007","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.actbio.2020.01.039_bib0008","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.biomaterials.2016.04.010","article-title":"Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy","volume":"96","author":"Sasso","year":"2016","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.actbio.2020.01.039_bib0009","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/1756283X16667909","article-title":"Immunotherapy in pancreatic cancer treatment: a new frontier","volume":"10","author":"Thind","year":"2017","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"1","key":"10.1016\/j.actbio.2020.01.039_bib0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/cancers10010006","article-title":"Immune evasion in pancreatic cancer: from mechanisms to therapy","volume":"10","author":"Martinez-Bosch","year":"2018","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.actbio.2020.01.039_bib0011","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.actbio.2020.01.039_bib0012","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1158\/1078-0432.CCR-11-1331","article-title":"Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives","volume":"17","author":"Godin-Ethier","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.actbio.2020.01.039_bib0013","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1535-7163.MCT-09-0628","article-title":"Hydroxyamidine inhibitors of indoleamine-2, 3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors","volume":"9","author":"Koblish","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"17","key":"10.1016\/j.actbio.2020.01.039_bib0014","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.actbio.2020.01.039_bib0015","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jamcollsurg.2007.12.014","article-title":"Expression of indoleamine 2, 3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection","volume":"206","author":"Witkiewicz","year":"2008","journal-title":"J. Am. Coll. Surg."},{"issue":"5","key":"10.1016\/j.actbio.2020.01.039_bib0016","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI31178","article-title":"Indoleamine 2, 3-dioxygenase and tumor-induced tolerance","volume":"117","author":"Munn","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.actbio.2020.01.039_bib0017","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol."},{"issue":"S3","key":"10.1016\/j.actbio.2020.01.039_bib0018","doi-asserted-by":"crossref","first-page":"P250","DOI":"10.1186\/2051-1426-2-S3-P250","article-title":"A phase I study of NLG919 for adult patients with recurrent advanced solid tumors","volume":"2","author":"Nayak","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.actbio.2020.01.039_bib0019","doi-asserted-by":"crossref","first-page":"13443","DOI":"10.1038\/ncomms13443","article-title":"An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy","volume":"7","author":"Chen","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.actbio.2020.01.039_bib0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.actbio.2020.01.039_bib0021","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.addr.2010.11.005","article-title":"Extravasation of polymeric nanomedicines across tumor vasculature","volume":"63","author":"Danquah","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.actbio.2020.01.039_bib0022","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.actbio.2020.01.039_bib0023","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nmat3792","article-title":"Strategies for advancing cancer nanomedicine","volume":"12","author":"Chauhan","year":"2013","journal-title":"Nat. Mater."},{"issue":"12","key":"10.1016\/j.actbio.2020.01.039_bib0024","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nnano.2011.166","article-title":"Accumulation of sub-100nm polymeric micelles in poorly permeable tumours depends on size","volume":"6","author":"Cabral","year":"2011","journal-title":"Nat. Nanotechnol."},{"issue":"46","key":"10.1016\/j.actbio.2020.01.039_bib0025","doi-asserted-by":"crossref","first-page":"8649","DOI":"10.1002\/anie.201003142","article-title":"A nanoparticle size series for in vivo fluorescence imaging","volume":"49","author":"Popovi\u0107","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"issue":"48","key":"10.1016\/j.actbio.2020.01.039_bib0026","doi-asserted-by":"crossref","first-page":"11417","DOI":"10.1002\/anie.201104449","article-title":"Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration","volume":"50","author":"Chauhan","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.actbio.2020.01.039_bib0027","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.actbio.2016.07.014","article-title":"A prodrug micellar carrier assembled from polymers with pendant farnesyl thiosalicylic acid moieties for improved delivery of paclitaxel","volume":"43","author":"Sun","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2020.01.039_bib0028","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2017.04.005","article-title":"Ultrasmall polymeric nanocarriers for drug delivery to podocytes in kidney glomerulus","volume":"255","author":"Bruni","year":"2017","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.actbio.2020.01.039_bib0029","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.7150\/thno.38287","article-title":"High loading of hydrophobic and hydrophilic agents via small immunostimulatory carrier for enhanced tumor penetration and combinational therapy","volume":"10","author":"Sun","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.actbio.2020.01.039_bib0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jconrel.2017.05.006","article-title":"Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy","volume":"258","author":"Sun","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2020.01.039_bib0031","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jpba.2019.04.027","article-title":"Quantitation of paclitaxel, and its 6-alpha-OH and 3-para-OH metabolites in human plasma by LC-MS\/MS","volume":"172","author":"Christner","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.actbio.2020.01.039_bib0032","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-016-0119-z","article-title":"From bench to bedside a comprehensive review of pancreatic cancer immunotherapy","volume":"4","author":"Kunk","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"13\u201314","key":"10.1016\/j.actbio.2020.01.039_bib0033","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.addr.2013.09.016","article-title":"Can nanomedicines kill cancer stem cells?","volume":"65","author":"Zhao","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.actbio.2020.01.039_bib0034","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/aps.2017.44","article-title":"Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier","volume":"38","author":"Sun","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"issue":"34","key":"10.1016\/j.actbio.2020.01.039_bib0035","doi-asserted-by":"crossref","first-page":"9572","DOI":"10.1039\/c1cc11981h","article-title":"Dendrimers and miktoarm polymers based multivalent nanocarriers for efficient and targeted drug delivery","volume":"47","author":"Soliman","year":"2011","journal-title":"Chem. Commun."},{"issue":"7","key":"10.1016\/j.actbio.2020.01.039_bib0036","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1021\/acsnano.5b02017","article-title":"The role of micelle size in tumor accumulation, penetration, and treatment","volume":"9","author":"Wang","year":"2015","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.actbio.2020.01.039_bib0037","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000329413","article-title":"A syngeneic orthotopic murine model of pancreatic adenocarcinoma in the C57\/BL6 mouse using the Panc02 and 6606PDA cell lines","volume":"47","author":"Partecke","year":"2011","journal-title":"Eur. Surg. Res."},{"issue":"6","key":"10.1016\/j.actbio.2020.01.039_bib0038","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/BF00684850","article-title":"Mechanisms of resistance to 6-thioguanine in a murine pancreatic tumor","volume":"29","author":"Pan","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.actbio.2020.01.039_bib0039","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1021\/acsnano.5b00510","article-title":"Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice","volume":"9","author":"Meng","year":"2015","journal-title":"ACS Nano"}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706120300544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706120300544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:28:47Z","timestamp":1761672527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706120300544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":39,"alternative-id":["S1742706120300544"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2020.01.039","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2020.01.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}